TIGERMED (03347) announced its third-quarter results for 2025. The group recorded operating revenue of RMB5.026 billion in the first three quarters, representing a slight decrease of 0.82% year-on-year. Net profit attributable to shareholders rose 25.45% YoY to RMB1.02 billion, with basic earnings per share standing at RMB1.19.